Immune Classification of Hidradenitis Suppurativa: Modulation by Secukinumab

Article Medicine, General & Internal

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

Alexa B. Kimball et al.

Summary: Two randomized trials showed that secukinumab was clinically effective at rapidly improving signs and symptoms of moderate-to-severe hidradenitis suppurativa with a favorable safety profile and sustained response up to 52 weeks of treatment.

LANCET (2023)

Add to Collection

Review Dermatology

Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa A Systematic Review

Samuel Der Sarkissian et al.

Summary: This study systematically identified and evaluated the existing knowledge of biomarkers in hidradenitis suppurativa (HS). The findings showed that none of the identified biomarkers had sufficient clinical validity to be recommended for routine use in clinical practice. Standardization of goals and methods, as well as the integration of biomarkers into clinical trials, are important priorities for the management of HS.

JAMA DERMATOLOGY (2022)

Add to Collection

Article Surgery

Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa The SHARPS Randomized Clinical Trial

Falk G. Bechara et al.

Summary: The study investigated the efficacy and safety of adalimumab in combination with surgery for hidradenitis suppurativa, showing that adalimumab can improve clinical response by 14% across all body regions postoperatively. There was no increased risk of adverse events such as infection, complication, or hemorrhage with adalimumab compared to placebo after surgery.

JAMA SURGERY (2021)

Add to Collection

Article Dermatology